6917 logo

Andros Pharmaceuticals Co.,Ltd Stock Price

TPEX:6917 Community·NT$1.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6917 Share Price Performance

NT$30.55
12.50 (69.25%)
NT$30.55
12.50 (69.25%)
Price NT$30.55

6917 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards

Andros Pharmaceuticals Co.,Ltd Key Details

NT$0

Revenue

NT$0

Cost of Revenue

NT$0

Gross Profit

NT$0

Other Expenses

NT$0

Earnings

Last Reported Earnings
n/a
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About 6917

Founded
2008
Employees
n/a
CEO
n/a
WebsiteView website
www.andros.com.tw

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.

Recent 6917 News & Updates

Recent updates

No updates